Literature DB >> 29455396

Reversible cerebral vasoconstriction syndrome accompanied by hypomagnesemia.

Keiichi Hokkoku1, Yuichi Furukawa2, Junpei Yamamoto2, Yudai Uchida2, Masahiro Sonoo2.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 29455396     DOI: 10.1007/s10072-018-3281-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  5 in total

Review 1.  Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-10       Impact factor: 3.825

Review 2.  Reversible cerebral vasoconstriction syndrome.

Authors:  Anne Ducros
Journal:  Lancet Neurol       Date:  2012-10       Impact factor: 44.182

Review 3.  Magnesium sulfate for the treatment of eclampsia: a brief review.

Authors:  Anna G Euser; Marilyn J Cipolla
Journal:  Stroke       Date:  2009-02-10       Impact factor: 7.914

4.  Magnesium for Treatment of Reversible Cerebral Vasoconstriction Syndrome: Case Series.

Authors:  Christina Mijalski; Katarina Dakay; Cameron Miller-Patterson; Ali Saad; Brian Silver; Muhib Khan
Journal:  Neurohospitalist       Date:  2015-10-30

5.  Posterior reversible encephalopathy syndrome (PRES) and hypomagnesemia: A frequent association?

Authors:  A Chardain; V Mesnage; S Alamowitch; F Bourdain; S Crozier; T Lenglet; D Psimaras; S Demeret; P Graveleau; K Hoang-Xuan; R Levy
Journal:  Rev Neurol (Paris)       Date:  2016-06-28       Impact factor: 2.607

  5 in total
  1 in total

1.  Management and Clinical Outcome of Posterior Reversible Encephalopathy Syndrome in Pediatric Oncologic/Hematologic Diseases: A PRES Subgroup Analysis With a Large Sample Size.

Authors:  Marady Hun; Min Xie; Zhou She; Amin S Abdirahman; Cuifang Li; Feifeng Wu; Senlin Luo; Phanna Han; Rithea Phorn; Pan Wu; Haiyan Luo; Keke Chen; Jidong Tian; Wuqing Wan; Chuan Wen
Journal:  Front Pediatr       Date:  2021-07-01       Impact factor: 3.418

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.